![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
York Pharma | LSE:YRK | London | Ordinary Share | GB00B00QHC86 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.25 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
RNS Number : 3109K York Pharma plc 17 December 2008 TR-1: Notifications of Major Interests in Shares 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: York Pharma plc 2. Reason for notification (yes/no) An acquisition or disposal of voting rights An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached An event changing the breakdown of voting rights X Other (please specify): Dilution due to share capital increase 3. Full name of person(s) 1. Awal Trust Company Limited (as "parent undertaking" of Awal subject to notification Bank B.S.C. [Awal] and Saad Investments Company Ltd [SICL]) obligation: 2. Maan Abdulwahed Al-Sanea (as "parent undertaking" of Awal and SICL) 4. Full name of shareholder(s) Vidacos Nominees Pty Ltd. (as nominee for Awal) and (if different from 3): Bear Stearns Securities Corp (as nominee for SICL) 5. Date of transaction (and n/a date on which the threshold is crossed or reached if different): 6. Date on which issuer 16 December 2008 notified: 7. Threshold(s) that is/are 21% threshold was crossed, down to 20% crossed or reached: 8: Notified Details A: Voting rights attached to shares Class/type of shares Situation previous to the triggering Resulting situation after the triggering transaction If possible use ISIN code transaction Number of shares Number of voting Number of shares Number of voting Percentage of voting rights rights rights Direct Indirect Direct Indirect GB00B00QHC86 12,367,399 12,367,399 12,367,399 Nil 12,367,399 Nil 20.32% B: Financial Instruments Resulting situation after the triggering transaction Type of financial instrument Expiration date Exercise/ conversion No. of voting rights Percentage of voting period/date that may be acquired rights (if the instrument exercised/converted) - - - - - Total (A+B) Number of voting rights Percentage of voting rights 12,367,399 20.32% 9. Chain of controlled undertakings through which the voting rights and /or the financial instruments are effectively held, if applicable: Maan Abdulwahed Al-Sanea is subject to a notification obligation pursuant to DTR 5.2.1(e) as a "parent undertaking" of Awal, the indirect holder of 8,558,699 shares, and as a "parent undertaking" of SICL, the indirect holder of 3,808,700 shares; his joint holding amounts to 20.32%. Awal and SICL are indirectly owned by Awal Trust Company Limited ("ATCL") as trustee of the Saad STAR Trust. ATCL is therefore subject to notification obligation pursuant to DTR 5.2.1(e) as a "parent undertaking" of Awal and SICL. Proxy Voting: 10. Name of proxy holder: - 11. Number of voting rights proxy holder will cease to hold: - 12. Date on which proxy holder will cease to hold voting rights: - 13. Additional information: Awal Bank D.S.C. indirectly holds 8,558,699 (14.06%) shares through Vidacos Nominees Pty Ltd. Saad Investments Company Limited indirectly holds 3,808,700 (6.26%) shares through Bear Stearn Securities Corp. 14 Contact name: Christopher C Hart 15. Contact telephone number : +41 22 715 0303 This information is provided by RNS The company news service from the London Stock Exchange END HOLBXBDDUBBGGIR
1 Year York Pharma Chart |
1 Month York Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions